中国成人戈谢病诊治专家共识(2020)

2020-06-23 中华医学会血液学分会红细胞疾病学组 中华医学杂志.2020.100(24):1841-1849. 发表于安徽省

戈谢病(Gaucher disease,GD)是一种因溶酶体中葡萄糖脑苷脂酶功能缺陷导致的罕见常染色体隐性遗传代谢病。该病由于葡萄糖脑苷脂酶基因突变导致机体葡萄糖脑苷脂酶(glucocerebmsid

中文标题:

中国成人戈谢病诊治专家共识(2020)

发布日期:

2020-06-23

简要介绍:

戈谢病(Gaucher disease,GD)是一种因溶酶体中葡萄糖脑苷脂酶功能缺陷导致的罕见常染色体隐性遗传代谢病。该病由于葡萄糖脑苷脂酶基因突变导致机体葡萄糖脑苷脂酶(glucocerebmsidase;又称酸性β ‑葡萄糖苷酶,acid β‑glucosidase)活性缺乏或降低,造成其底物葡萄糖脑苷脂(glucocerebroside,也称为葡糖神经酰胺)在肝、脾、肾、骨骼、肺、甚至脑的巨噬细胞中贮积,形成典型的贮积细胞即“戈谢细胞”,导致受累组织器官出现病变,临床表现为多脏器受累并呈进行性加重。

为促进戈谢病领域的学术发展及临床诊疗的规范,结合近年来戈谢病文献,参考国内外权威指南共识,结合专家组临床诊治经验,对2015版的中国戈谢病诊治专家共识进行了更新,并进一步细化了成人疾病初诊评估、筛查、随访等内容,旨在使其可操作性更强,更适应临床医师日常诊疗工作需要。

下载附件:

(因为版权问题,不支持下载)

评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=958985, encodeId=45e695898529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079f5483670, createdName=ms8000002026957742, createdTime=Wed Apr 21 09:49:06 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953563, encodeId=b3a09535632a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:31 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923766, encodeId=df26923e66f4, content=指导了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:10:34 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888288, encodeId=1fbb8882887e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Sep 25 15:01:17 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805579, encodeId=baa78055e9a1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dfd2637793, createdName=152264d998m, createdTime=Sat Aug 01 11:13:30 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2021-04-21 ms8000002026957742

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=958985, encodeId=45e695898529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079f5483670, createdName=ms8000002026957742, createdTime=Wed Apr 21 09:49:06 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953563, encodeId=b3a09535632a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:31 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923766, encodeId=df26923e66f4, content=指导了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:10:34 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888288, encodeId=1fbb8882887e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Sep 25 15:01:17 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805579, encodeId=baa78055e9a1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dfd2637793, createdName=152264d998m, createdTime=Sat Aug 01 11:13:30 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2021-04-03 12528eb6m08暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=958985, encodeId=45e695898529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079f5483670, createdName=ms8000002026957742, createdTime=Wed Apr 21 09:49:06 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953563, encodeId=b3a09535632a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:31 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923766, encodeId=df26923e66f4, content=指导了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:10:34 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888288, encodeId=1fbb8882887e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Sep 25 15:01:17 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805579, encodeId=baa78055e9a1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dfd2637793, createdName=152264d998m, createdTime=Sat Aug 01 11:13:30 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2021-02-08 12314969m72暂无昵称

    指导了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=958985, encodeId=45e695898529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079f5483670, createdName=ms8000002026957742, createdTime=Wed Apr 21 09:49:06 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953563, encodeId=b3a09535632a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:31 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923766, encodeId=df26923e66f4, content=指导了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:10:34 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888288, encodeId=1fbb8882887e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Sep 25 15:01:17 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805579, encodeId=baa78055e9a1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dfd2637793, createdName=152264d998m, createdTime=Sat Aug 01 11:13:30 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-09-25 12314969m72暂无昵称

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=958985, encodeId=45e695898529, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=079f5483670, createdName=ms8000002026957742, createdTime=Wed Apr 21 09:49:06 CST 2021, time=2021-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953563, encodeId=b3a09535632a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210409/24a3c88bf27e42c89be15f164e992883/47fd023e77434094b3d596b55574979b.jpg, createdBy=7d082543841, createdName=12528eb6m08暂无昵称, createdTime=Sat Apr 03 16:20:31 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923766, encodeId=df26923e66f4, content=指导了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:10:34 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888288, encodeId=1fbb8882887e, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Sep 25 15:01:17 CST 2020, time=2020-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805579, encodeId=baa78055e9a1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8dfd2637793, createdName=152264d998m, createdTime=Sat Aug 01 11:13:30 CST 2020, time=2020-08-01, status=1, ipAttribution=)]
    2020-08-01 152264d998m

    学习了

    0

拓展阅读

中国戈谢病诊治专家共识2011

溶酶体贮积病医疗协作组《中国戈谢病诊治专家共识》编委会 · 2011-03-15